For drug information, click here.

Small victories add up.

At Diplomat, we know that multiple myeloma requires the best of us. The complexity of the condition, unique protocols and hope of new treatment brings all our people, services and resources together. We’re here for patients in every way, and we’re here to help prescribers give them every advantage to succeed. We’re here for patients in every way possible, and we’re here to help prescribers give each patient every advantage to succeed.

Over
93%


adherence to oncology medication1

In 2015, we
connected
patients with

$40M


in third-party
oncology copay
assistance2

24/7


support

Diplomat is here to help you.

mm1

Rely on our knowledge

On-staff pharmacists versed in treatment options, side effects, drug interactions and more. Patient advocates meet with patients and prescribers and help build education and awareness. Clinical services work with the pharmaceutical industry to understand the myeloma pipeline and help successfully launch new programs.

mm1

Rely on our people

Our patient care coordinators work directly with myeloma patients, providing them information specific to their needs and treatment. Our dedicated prior authorization and appeals teams help provide access. And copay assistance services work to reduce or remove financial burden.

mm1

Rely on our tools

We innovate methods and tools to help patients stay adherent to treatment. CarePak™ adherence packages that organize medication by their specific protocol and timing needs. Technologies better connect us with a patient’s entire care team. Compounding services make difficult protocols a bit easier on patients.

1. Diplomat Adherence Reporting, 2015. Average capped MPR across oncolytic therapeutic categories.
2. Diplomat Funding Results, 2015

Let’s fight myeloma, together.

Have a question? Send us a note.

Twitter